Galantamine
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Galantamine: From Alzheimer’s Disease to Psychogenic Movement Disorders
One-Sentence Summary
Galantamine is a cholinesterase inhibitor originally used to treat mild-to-moderate Alzheimer’s disease dementia. The TxGNN model predicts it may be effective for Psychogenic Movement Disorders, but this specific direction is currently supported by 0 clinical trials and 0 publications — it is a pure knowledge-graph prediction with no corroborating evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Alzheimer’s disease (mild-to-moderate dementia) |
| Predicted New Indication | Psychogenic Movement Disorders |
| TxGNN Prediction Score | 99.90% |
| Evidence Level | L5 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is currently not available in this evidence pack (marked as a data gap). Based on known pharmacology, galantamine is an acetylcholinesterase inhibitor that also acts as an allosteric potentiator of nicotinic acetylcholine receptors; its efficacy in Alzheimer’s disease dementia is well established, and this cholinergic-enhancing action is the presumed basis for the TxGNN model surfacing it against other indications.
However, for this specific predicted indication — psychogenic movement disorders — there is no known cholinergic mechanistic pathway linking galantamine’s pharmacology to the condition. The rationale supplied alongside this prediction states explicitly that this is a TxGNN knowledge-graph output only, without any supporting clinical or preclinical evidence. The prediction score is high, but score alone does not establish biological plausibility.
Notably, the wider batch of TxGNN predictions generated for galantamine does include candidates with a clearer cholinergic-movement rationale (e.g. extrapyramidal/movement disease and tardive dyskinesia — see note below), which have actual trial and literature support. Psychogenic movement disorders, by contrast, sits at the purely speculative end of this drug’s prediction set.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
UK Market Information
No UK marketing authorisation is currently recorded for galantamine in this dataset (market status: not marketed; 0 licences held). No product-level licence information is therefore available to tabulate.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale: This prediction is supported only by a TxGNN knowledge-graph score, with no clinical trials, no literature, and no established mechanistic link between cholinergic modulation and psychogenic movement disorders. A blocking data gap (missing MHRA/SmPC warnings and contraindications) also prevents this candidate from entering initial safety screening.
To proceed, the following is needed:
- MHRA-approved SmPC/PIL data to establish warnings and contraindications (currently blocking)
- Detailed mechanism of action data from DrugBank
- Preclinical or mechanistic studies specifically linking cholinergic modulation to psychogenic movement disorders
- Re-evaluation against alternative predicted indications from the same batch with stronger evidentiary support (see note below)
Note on other TxGNN predictions for galantamine: This evidence pack contains nine ranked predictions for galantamine. Two others carry materially more evidence than the top-ranked candidate reported above and may warrant separate evaluation: extrapyramidal and movement disease (L3, decision stage S1, “Research Question” — supported by two completed Phase 2/4 RCTs and a 2025 systematic review, though evidence is mixed, with some data suggesting AChEIs can induce rather than treat movement disorders) and lingual-facial-buccal dyskinesia (L3, S1, “Research Question” — supported by a Phase 3-equivalent RCT, two Cochrane reviews, and a pharmacovigilance study, again with conflicting directionality). Both are more scientifically substantive than the rank-1 prediction covered in this report and are better candidates for further review.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.